Breaking News

Thursday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
VCRA Vocera $31.26 0.36 (1.17%) , TDOC Teladoc $66.65 0.815 (1.24%) 08:00 02/14/19 02/14 08:00 02/14/19 08:00 Recommendations	Vocera, Teladoc analyst commentary at Jefferies » Vocera guidance relates… Vocera guidance relates more to device launch than competition, says Jefferies. After hosting meetings with a host of managements, Jefferies analyst Sean Dodge says Vocera Communications' (VCRA) "weak" revenue guidance "seems to relate more to the Smartbadge launch than to competitive intrusion." Further, interest in Teladoc's (TDOC) virtual-first offering continues to grow, with a Blues plan now seeking regulatory approval to launch an entirely new plan designed on the concept, Dodge tells investors in a research note. The analyst keeps Buy ratings on both Vocera and Teladoc. VCRA Vocera $31.26 0.36 (1.17%) TDOC Teladoc $66.65 0.815 (1.24%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Feb

Monday
TDOC Teladoc $62.55 0.32 (0.51%) 05:18 02/11/19 02/11 05:18 02/11/19 05:18 Recommendations	Teladoc analyst commentary at Piper Jaffray » Piper reiterates… Piper reiterates Overweight on Teladoc after study on avoidable ED visits. In a study published last week, Premier identified 4.3M, or 18%, of emergency department visits by chronically ill patients that could have been avoided, but instead cost the system $8.3B, Piper Jaffray analyst Sean Wieland tells investors in a research note. The analyst believes this data point "attests to the need for increased access to care at lower costs, which can be addressed by telemedicine." He reiterates an Overweight rating on Teladoc with an $88 price target. Further reduction of barriers to access "would be another feather in the cap for the telemedicine industry," says Wieland. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
HOME At Home Group $22.00 0.07 (0.32%) , TDOC Teladoc $63.93 1.86 (3.00%) … 10:13 01/31/19 01/31 10:13 01/31/19 10:13 Initiation	Fly Intel: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Gordon Haskett. 2. Teladoc (TDOC) initiated with a Buy at Berenberg. 3. Intercept (ICPT) initiated with an Outperform at Credit Suisse. 4. Recro Pharma (REPH), BioDelivery Sciences (BDSI), and Supernus (SUPN) were assumed with a Buy at Janney Montgomery Scott. 5. Green Thumb Industries (GTBIF) initiated with a Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. HOME At Home Group $22.00 0.07 (0.32%) TDOC Teladoc $63.93 1.86 (3.00%) ICPT Intercept $118.61 2.53 (2.18%) REPH Recro Pharma $8.10 0.21 (2.66%) BDSI BioDelivery Sciences $4.62 0.12 (2.67%) SUPN Supernus $38.00 0.9 (2.43%) GTBIF Green Thumb Industries $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	18 May
TDOC Teladoc $62.07 1.28 (2.11%) 08:28 01/31/19 01/31 08:28 01/31/19 08:28 Initiation	Teladoc initiated at Berenberg » Teladoc initiated with a… Teladoc initiated with a Buy at Berenberg. Berenberg initiated Teladoc with a Buy and $80 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TDOC Teladoc $60.49 1.25 (2.11%) 08:43 01/17/19 01/17 08:43 01/17/19 08:43 Recommendations	Teladoc analyst commentary at Jefferies » Teladoc catalysts give… Teladoc catalysts give reason to own stock now, says Jefferies. Jefferies analyst Sean Dodge says his firm's updated market share analysis continues to show Teladoc as the dominant vendor. SimilarWeb data points to BetterHelp usage down quarter-over-quarter in November but stabilizing in December and up in January, Dodge tells investors in a research note. There are "multiple upcoming catalysts, giving investors a reason to own the stock now," says the analyst. He points out Teladoc shares are still down over 30% from their late-September highs. Dodge keeps a Buy rating on the stock with a $95 price target, which represents 57% upside potential. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
TDOC Teladoc $55.49 -0.08 (-0.14%) , UNH UnitedHealth $247.67 2.63 (1.07%) 08:09 01/14/19 01/14 08:09 01/14/19 08:09 Upgrade	Teladoc, UnitedHealth rating change at Baird » Baird upgrades Teladoc to… Baird upgrades Teladoc to Outperform on valuation, UnitedHealth deal potential. As reported previously, Baird analyst Matthew Gillmor upgraded Teladoc (TDOC) to Outperform from Neutral. The analyst believes it remains an attractive secular growth story as plan sponsors are reconfiguring benefit designs for "virtual first" healthcare. He also believes its valuation is looking more attractive and the Street estimates appear achievable. Gillmor also believes the company is working on a contract with UnitedHealth (UNH) to serve a large patient population within the latter, which would be a positive catalyst. Gillmor has an $80 price target on Teladoc shares. TDOC Teladoc $55.49 -0.08 (-0.14%) UNH UnitedHealth $247.67 2.63 (1.07%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	15 Jan 19 Feb 28 May
TDOC Teladoc $55.49 -0.08 (-0.14%) 06:08 01/14/19 01/14 06:08 01/14/19 06:08 Upgrade	Teladoc rating change at Baird » Teladoc upgraded to… Teladoc upgraded to Outperform from Neutral at Baird 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TDOC Teladoc $52.08 2.7 (5.47%) , EVH Evolent Health $20.92 0.92 (4.60%) … 05:40 01/08/19 01/08 05:40 01/08/19 05:40 Recommendations	Teladoc, Evolent Health, Cerner analyst commentary at Piper Jaffray » Piper survey finds… Piper survey finds 'remarkable increase' in receptivity to telemedicine. Piper Jaffray analyst Sean Wieland says his firm's third annual consumer healthcare survey reveals a "remarkable increase" in consumer receptivity to telemedicine. The likelihood of someone choosing telemedicine has doubled year-over-year to 61% versus 28%, and half of consumers suggest they would consider a virtual behavioral therapist, Wieland tells investors in a research note. Even the 65 and over population is warming up to telemedicine, says the analyst. He reiterates an Overweight rating on Teladoc (TDOC). Wieland also believes Evolent Health (EVH) and Cerner (CERN) are well positioned for this trend. TDOC Teladoc $52.08 2.7 (5.47%) EVH Evolent Health $20.92 0.92 (4.60%) CERN Cerner $51.91 -0.33 (-0.63%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Jan
EVH Evolent Health $19.29 -0.35 (-1.78%) , OMCL Omnicell $59.05 -0.79 (-1.32%) … 06:55 01/04/19 01/04 06:55 01/04/19 06:55 Recommendations	Evolent Health, Omnicell, Tabula Rasa HealthCare, Teladoc analyst commentary at Oppenheimer » Healthcare IT pullbacks… Healthcare IT pullbacks create 'great' opportunities, says Oppenheimer. Oppenheimer analyst Mohan Naidu says that recent pullbacks are creating some "great" opportunities in Healthcare IT and believes, in particular, Evolent Health (EVH), Omnicell (OMCL), Tabula Rasa HealthCare (TRHC) and Teledoc (TDOC) stand out. In a research note to investors, Naidu contends that Evolent will gain from the finalized CMS regulations and increased push to risk-based models, and says Omnicell's story is significantly de-risked with traction in XT implementations. He also adds that Tabula Rasa should deliver on multiple growth drivers brewing in 2019 including PACE. and that despite the near-term distractions, Teledoc's story remains intact with significant telehealth adoption and utilization focus. EVH Evolent Health $19.29 -0.35 (-1.78%) OMCL Omnicell $59.05 -0.79 (-1.32%) TRHC Tabula Rasa HealthCare $57.44 -3.7 (-6.05%) TDOC Teladoc $46.23 -1.99 (-4.13%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TDOC Teladoc $51.16 -1.29 (-2.46%) 08:47 12/17/18 12/17 08:47 12/17/18 08:47 Earnings	Teladoc backs FY18 EPS view to ($1.48)-($1.50), consensus ($1.49) » Backs FY18 revenue view… Backs FY18 revenue view to $414M-$416M, consensus $415.23M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial